Telitacicept combined with glucocorticoids in adult-onset IgA vasculitis nephritis: A case report.
Аннотация
AIMS: IgA vasculitis with nephritis (IgAVN), a severe renal manifestation of IgA vasculitis, is rare in adults and associated with high morbidity. Current therapies are suboptimal, highlighting the need for novel approaches. This case study evaluates telitacicept, a dual BAFF/APRIL inhibitor, in a high-risk adult IgAVN patient.
MATERIALS AND
METHODS
A 45-year-old male with biopsy-confirmed IgAVN, progressive renal impairment (estimated glomerular filtration rate (eGFR): 44 mL/min/1.73m2), and significant proteinuria (1.08 g/day) was treated with weekly subcutaneous telitacicept (160 mg) and oral prednisone. Clinical outcomes were assessed over 6 months.
RESULTS
After 6 months, the patient showed rapid and sustained improvement: proteinuria decreased by 78.7% (from 1.08 to 0.23 g/day), and renal function stabilized (serum creatinine: 90.9 μmol/L; eGFR preserved). Prednisone was tapered and discontinued without relapse, demonstrating telitacicept's steroid-sparing effect. No treatment-related adverse events occurred.
CONCLUSION
Telitacicept appeared to reduced proteinuria, stabilized renal function, and allowed corticosteroid withdrawal in refractory IgAVN. These findings suggest dual BAFF/APRIL inhibition as a promising strategy for IgA-mediated diseases, warranting further studies to confirm its role in IgAVN.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.